Holen Sie sich die Stockscreener-App
7.54
0.60%
-0.03
Schlusskurs vom Vortag:
$7.51
Offen:
$7.45
24-Stunden-Volumen:
14,350
Relative Volume:
0.02
Marktkapitalisierung:
$308.05M
Einnahmen:
$142.09M
Nettoeinkommen (Verlust:
$-35.73M
KGV:
-8.5857
EPS:
-0.8782
Netto-Cashflow:
$-22.20M
1W Leistung:
-5.86%
1M Leistung:
-7.04%
6M Leistung:
-20.75%
1J Leistung:
-70.66%
1-Tages-Spanne:
$7.45
$7.57
1-Wochen-Bereich:
$6.825
$8.08
52-Wochen-Spanne:
$6.32
$27.13
Rxsight Inc Stock (RXST) Company Profile
Firmenname
Rxsight Inc
Sektor
Branche
Telefon
949-521-7822
Adresse
100 COLUMBIA STREET, ALISO VIEJO
Compare RXST vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
7.465 | 312.39M | 142.09M | -35.73M | -22.20M | -0.8782 |
|
ABT
Abbott Laboratories
|
110.14 | 192.10B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
356.22 | 137.25B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
89.94 | 115.41B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.86 | 103.81B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
85.24 | 49.82B | 6.07B | 1.06B | 1.34B | 1.8063 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Eingeleitet | William Blair | Mkt Perform |
| 2025-07-15 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-07-10 | Herabstufung | Jefferies | Buy → Hold |
| 2025-07-09 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-07-09 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-07-09 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-04-15 | Eingeleitet | Piper Sandler | Neutral |
| 2025-04-09 | Herabstufung | UBS | Buy → Neutral |
| 2025-04-04 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2025-04-03 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-12-20 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | Eingeleitet | UBS | Buy |
| 2024-10-29 | Eingeleitet | Jefferies | Buy |
| 2024-08-20 | Bestätigt | Needham | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-05-07 | Bestätigt | BTIG Research | Buy |
| 2023-12-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-12 | Eingeleitet | Stifel | Buy |
| 2023-12-04 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-04-13 | Eingeleitet | Oppenheimer | Outperform |
| 2022-12-12 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-08 | Eingeleitet | Needham | Buy |
Alle ansehen
Rxsight Inc Aktie (RXST) Neueste Nachrichten
(RXST) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Stifel Nicolaus Has Lowered Expectations for RxSight (NASDAQ:RXST) Stock Price - MarketBeat
Stifel cuts RxSight stock price target to $9 on revenue guidance - Investing.com
RxSight Inc. (RXST) PT Lowered to $9 at Stifel After Prudent Guidance - StreetInsider
RxSight Earnings Call: Strong Core, Cautious Outlook - TipRanks
How The RxSight (RXST) Investment Story Is Shifting With New Guidance And CFO Change - Yahoo Finance
Midday Stock Roundup: Staar Falls 3.8% After Q4 Miss - Orange County Business Journal
Forecast Cut: Will RxSight Inc stock go up in YEARJuly 2025 Outlook & High Return Stock Watch Alerts - baoquankhu1.vn
RxSight (RXST) Q4 2025 Earnings Call Transcript - AOL.com
RxSight (RXST) COO granted 32,218 RSUs vesting through 2029 - Stock Titan
2026-03-03 | RxSight, Inc. (RXST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:RXST | Press Release - Stockhouse
RXST Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Short Interest in RxSight, Inc. (NASDAQ:RXST) Expands By 29.3% - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
2026-03-01 | Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Shareholders to Inquire about Securities Investigation | NDAQ:RXST | Press Release - Stockhouse
Artisan Partners Limited Partnership Cuts Position in RxSight, Inc. $RXST - MarketBeat
RXST Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
RxSight, Inc. (RXST) Investor Outlook: Exploring a 28% Potential Upside in the Medical Devices Sector - DirectorsTalk Interviews
RxSight, Inc. (NASDAQ:RXST) Q4 2025 Earnings Call Transcript - Insider Monkey
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), RxSight (RXST) and Cardiff Oncology (CRDF) - The Globe and Mail
RxSight Reports Fourth Quarter and Fiscal Year Financial Results - VisionMonday.com
Responsive Playbooks and the RXST Inflection - Stock Traders Daily
Needham reiterates Buy on RxSight stock, keeps $13 target By Investing.com - Investing.com Australia
RxSight (RXST) Loss Deepens In Q4 Results Reinforcing Bearish Profitability Narratives - simplywall.st
What 5 Analyst Ratings Have To Say About RxSight - Benzinga
UBS Increases Price Target for RXST to $9.00 While Maintaining N - GuruFocus
RxSight (NASDAQ:RXST) Given New $9.00 Price Target at UBS Group - MarketBeat
RXST: Piper Sandler Lowers Price Target to $10.00, Maintains Neu - GuruFocus
RxSight (NASDAQ:RXST) Price Target Lowered to $10.00 at Piper Sandler - MarketBeat
UBS Adjusts Price Target on RxSight to $9 From $8, Maintains Neutral Rating - marketscreener.com
RxSight, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Needham Reiterates Buy Rating on RxSight Inc. (RXST) - StreetInsider
RxSight Q4 Earnings Call Highlights - MarketBeat
RxSight (NASDAQ:RXST) Issues Earnings Results - MarketBeat
RxSight, Inc. (RXST) Posts Fourth Quarter Loss, Surpasses Revenue Expectations - Bitget
Earnings call transcript: RxSight Q4 2025 beats EPS, revenue forecasts - Investing.com
RxSight, Inc. (RXST) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Earnings call transcript: RxSight Q4 2025 beats EPS, revenue forecasts By Investing.com - Investing.com Australia
RXSIGHT INC (NASDAQ:RXST) Reports Q4 Beat but Cautious 2026 Outlook Weighs on Shares - ChartMill
Rxsight earnings beat by $0.32, revenue topped estimates - Investing.com Canada
RxSight, Inc. (RXST) Tops Q4 EPS by 32c - StreetInsider
RxSight (RXST) Releases Q4 2025 Earnings: Revenue Down but Beats Estimates; Loss Narrows, EPS Beats - Quiver Quantitative
RxSight, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
RXSight, Inc. Reports Fourth Quarter and 2025 Results; Issues 2026 Guidance - The Manila Times
RxSight (RXST) grows LAL volume but posts wider 2025 loss, soft 2026 outlook - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Investors to Connect - Stockhouse
Earnings Update: Will RxSight Inc face regulatory challenges2025 Year in Review & Low Drawdown Trading Strategies - baoquankhu1.vn
Earnings To Watch: RxSight Inc (RXST) Reports Q4 2025 Result - GuruFocus
Analyst Calls: Can ProQR Therapeutics NV withstand a market correctionBuy Signal & Daily Momentum Trading Reports - baoquankhu1.vn
2026-02-22 | Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Stockholders to Inquire about Securities Investigation | NDAQ:RXST | Press Release - Stockhouse
RxSight, Inc. (RXST) initiated at market perform as firm seeks sales reacceleration - MSN
Finanzdaten der Rxsight Inc-Aktie (RXST)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.23%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):